University of Colorado Researchers Identify Deadly Prostate Cancer Subtype

University of Colorado Researchers Identify Deadly Prostate Cancer Subtype
Researchers from the  Cancer Center recently defined a new subtype of deadly prostate cancer that is characterized by loss of the MAP3K7 and CHD1 genes. According to the study findings, about 50% of men with prostate cancer that have the combined gene deletions will present persistent prostate cancer. Approximately 10% of all prostate cancer have this combination. The study titled "Coordinate Loss of MAP3K7 and CHD1Promotes Aggressive Prostate Cancer" is published in the journal Cancer Research. “This was a multi-disciplinary study by multiple investigators at multiple institutions showing a particularly aggressive type of prostate cancer that kills people,” said Scott Cramer, PhD, investigator at the CU Cancer Center, professor in the CU School of Medicine Department of Pharmacology, and the paper’s senior author in a recent news release. Lindsey Rodrigues, PhD, James Costello, PhD, and Scott Cramer, PhD from the University of Colorado began their research observing slow-growing and less dangerous, whereas others tend to be fast-growing and dangerous prostate cancers. Then the researchers questioned if the difference between the two types of prostate cancer would be due to genetic differences. They analyzed tumor samples from public databases and found that MAP3K7-CHD1 deletions were a specific to aggressive type cancer, accounting for 25% of deaths related to prostate cancer (nearly 7,500 men each year). The researchers then implanted artificial prostate tumors in mice with these gene deletions derived from a stem-cell model. “This is a unique model,” Cramer said in the news release. “We grow mouse prostate stem cells in culture in which we’ve knocked down these two genes. Then we combine these engineered stem cells with prostate cel
Subscribe or to access all post and page content.